Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lifecare AS ( (DE:LFC0) ) has shared an update.
Lifecare ASA has completed initial testing of the electronics for its Continuous Glucose Monitoring implant, marking a significant milestone in its CE-marking process and regulatory strategy. The successful electromagnetic compatibility tests confirm the system’s stable technical foundation, allowing the company to proceed with further optimizations and remain on track for first-in-human clinical trials this year, with a commercial launch anticipated in 2027.
More about Lifecare AS
Lifecare ASA is a medtech company specializing in the development of next-generation Continuous Glucose Monitoring (CGM) technology for diabetes management. The company focuses on using osmotic pressure as a sensing principle to monitor various body analytes, aiming to bring advanced CGM systems to market.
Average Trading Volume: 45,432
Current Market Cap: NOK106M
See more insights into LFC0 stock on TipRanks’ Stock Analysis page.